Pharmacological management of interstitial cystitis /bladder pain syndrome and the role cyclosporine and other immunomodulating drugs play

References

• Hunner G. A rare type of bladder ulcer in women; report of cases. Boston Med Surg J. 1915;172:660–664.
   Google Scholar
• Fall M, Baranowski AP, Elneil S, et al. EAU guidelines on chronic pelvic pain. Eur Urol. 2010;57(1):35–48.
   PubMed Web of Science ®Google Scholar
• Gillenwater JY, Wein AJ. Summary of the National Institute of arthritis, diabetes, digestive and kidney diseases workshop on interstitial cystitis, National Institutes of Health, Bethesda, Maryland, August 28–29,1987. J Urol. 1988;140(1):203–206.
   PubMed Web of Science ®Google Scholar
• Hanno PM, Burks DA, Clemens JQ, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J Urol. 2011;185(6):2162–2170.
   PubMed Web of Science ®Google Scholar
• Fall M, Logadottir Y, Peeker R. Interstitial cystitis is bladder pain syndrome with Hunner’s lesion. Int J Urol. 2014;21(Suppl 1):79–82.
   PubMed Web of Science ®Google Scholar
• Logadottir Y, Fall M, Kabjorn-Gustafsson C, et al. Clinical characteristics differ considerably between phenotypes of bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol. 2012;46(5):365–370.
   PubMed Web of Science ®Google Scholar
• Berry SH, Elliott MN, Suttorp M, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. J Urol. 2011;186(2):540–544.
   PubMed Web of Science ®Google Scholar
• Konkle KS, Berry SH, Elliott MN, et al. Comparison of an interstitial cystitis/bladder pain syndrome clinical cohort with symptomatic community women from the RAND Interstitial Cystitis Epidemiology study. J Urol. 2012;187(2):508–512.
   PubMed Web of Science ®Google Scholar
• Waxman JA, Sulak PJ, Kuehl TJ. Cystoscopic findings consistent with interstitial cystitis in normal women undergoing tubal ligation. J Urol. 1998;160(5):1663–1667.
   PubMed Web of Science ®Google Scholar
• Peeker R, Fall M. Treatment guidelines for classic and non-ulcer interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(1):23–32.
   PubMed Web of Science ®Google Scholar
• Simon LJ, Landis JR, Erickson DR, et al. The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics. Urology. 1997;49(5A Suppl):64–75.
   PubMed Web of Science ®Google Scholar
• Chancellor MB, Yoshimura N. Treatment of interstitial cystitis. Urology. 2004;63(3 Suppl 1):85–92.
   PubMed Web of Science ®Google Scholar
• Buffington CA, Woodworth BE. Excretion of fluorescein in the urine of women with interstitial cystitis. J Urol. 1997;158(3 Pt 1):786–789.
   PubMed Web of Science ®Google Scholar
• Keay S, Warren JW, Zhang CO, et al. Antiproliferative activity is present in bladder but not renal pelvic urine from interstitial cystitis patients. J Urol. 1999;162(4):1487–1489.
   PubMed Web of Science ®Google Scholar
• Conrads TP, Tocci GM, Hood BL, et al. CKAP4/p63 is a receptor for the frizzled-8 protein-related antiproliferative factor from interstitial cystitis patients. J Biol Chem. 2006;281(49):37836–37843.
   PubMed Web of Science ®Google Scholar
• Kim J, Keay SK, Freeman MR. Heparin-binding epidermal growth factor-like growth factor functionally antagonizes interstitial cystitis antiproliferative factor via mitogen-activated protein kinase pathway activation. BJU Int. 2009;103(4):541–546.
   PubMed Web of Science ®Google Scholar
• Slobodov G, Feloney M, Gran C, et al. Abnormal expression of molecular markers for bladder impermeability and differentiation in the urothelium of patients with interstitial cystitis. J Urol. 2004;171(4):1554–1558.
   PubMed Web of Science ®Google Scholar
• Heinrich M, Oberbach A, Schlichting N, et al. Cytokine effects on gap junction communication and connexin expression in human bladder smooth muscle cells and suburothelial myofibroblasts. PLoS One. 2011;6(6):e20792.
   PubMed Web of Science ®Google Scholar
• Birder LA, Wolf-Johnston A, Buffington CA, et al. Altered inducible nitric oxide synthase expression and nitric oxide production in the bladder of cats with feline interstitial cystitis. J Urol. 2005;173(2):625–629.
   PubMed Web of Science ®Google Scholar
• Lavelle JP, Meyers SA, Ruiz WG, et al. Urothelial pathophysiological changes in feline interstitial cystitis: a human model. Am J Physiol Renal Physiol. 2000;278(4):F540–553.
   PubMed Web of Science ®Google Scholar
• Zeng Y, Wu XX, Homma Y, et al. Uroplakin III-delta4 messenger RNA as a promising marker to identify nonulcerative interstitial cystitis. J Urol. 2007;178(4 Pt 1):1322–1327; discussion 1327.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, Seki S, Chancellor MB, et al. Targeting afferent hyperexcitability for therapy of the painful bladder syndrome. Urology. 2002;59(5 Suppl 1):61–67.
   PubMed Web of Science ®Google Scholar
• Denk F, McMahon SB. Chronic pain: emerging evidence for the involvement of epigenetics. Neuron. 2012;73(3):435–444.
   PubMed Web of Science ®Google Scholar
• Kairys AE, Schmidt-Wilcke T, Puiu T, et al. Increased brain gray matter in the primary somatosensory cortex is associated with increased pain and mood disturbance in patients with interstitial cystitis/painful bladder syndrome. J Urol. 2015;193(1):131–137.
   PubMed Web of Science ®Google Scholar
• Lutgendorf SK, Kreder KJ, Rothrock NE, et al. A laboratory stress model for examining stress and symptomatology in interstitial cystitis patients. Urology. 2001;57(6 Suppl 1):122.
   Google Scholar
• Kanter G, Komesu YM, Qaedan F, et al. Mindfulness-based stress reduction as a novel treatment for interstitial cystitis/bladder pain syndrome: a randomized controlled trial. Int Urogynecol J. 2016;27(11):1705–1711.
   PubMed Web of Science ®Google Scholar
• Homma Y, Ueda T, Tomoe H, et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int J Urol. 2009;16(7):597–615.
   PubMed Web of Science ®Google Scholar
• Cox A, Golda N, Nadeau G, et al. CUA guideline: diagnosis and treatment of interstitial cystitis/bladder pain syndrome. Can Urol Assoc J. 2016;10(5–6):E136–E155.
   PubMed Web of Science ®Google Scholar
• Foster HE Jr., Hanno PM, Nickel JC, et al. Effect of amitriptyline on symptoms in treatment naive patients with interstitial cystitis/painful bladder syndrome. J Urol. 2010;183(5):1853–1858.
   PubMed Web of Science ®Google Scholar
• van Ophoven A, Pokupic S, Heinecke A, et al. A prospective, randomized, placebo controlled, double-blind study of amitriptyline for the treatment of interstitial cystitis. J Urol. 2004;172(2):533–536.
   PubMed Web of Science ®Google Scholar
• Hertle L, van Ophoven A. Long-term results of amitriptyline treatment for interstitial cystitis. Aktuelle Urol. 2010;41(Suppl 1):S61–65.
   PubMed Web of Science ®Google Scholar
• Lilly JD, Parsons CL. Bladder surface glycosaminoglycans is a human epithelial permeability barrier. Surg Gynecol Obstet. 1990;171(6):493–496.
   PubMedGoogle Scholar
• Al-Zahrani AA, Gajewski JB. Long-term efficacy and tolerability of pentosan polysulphate sodium in the treatment of bladder pain syndrome. Can Urol Assoc J. 2011;5(2):113–118.
   PubMed Web of Science ®Google Scholar
• Jepsen JV, Sall M, Rhodes PR, et al. Long-term experience with pentosanpolysulfate in interstitial cystitis. Urology. 1998;51(3):381–387.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Barkin J, Forrest J, et al. Randomized, double-blind, dose-ranging study of pentosan polysulfate sodium for interstitial cystitis. Urology. 2005;65(4):654–658.
   PubMed Web of Science ®Google Scholar
• Neuhaus J, Schwalenberg T. Intravesical treatments of bladder pain syndrome/interstitial cystitis. Nat Rev Urol. 2012;9(12):707–720.
   PubMed Web of Science ®Google Scholar
• Perez-Marrero R, Emerson LE, Feltis JT. A controlled study of dimethyl sulfoxide in interstitial cystitis. J Urol. 1988;140(1):36–39.
   PubMed Web of Science ®Google Scholar
• Peeker R, Haghsheno MA, Holmang S, et al. Intravesical bacillus Calmette-Guerin and dimethyl sulfoxide for treatment of classic and nonulcer interstitial cystitis: a prospective, randomized double-blind study. J Urol. 2000;164(6):1912–1915; discussion 1915–1916.
   PubMed Web of Science ®Google Scholar
• Hung MJ, Chen YT, Shen PS, et al. Risk factors that affect the treatment of interstitial cystitis using intravesical therapy with a dimethyl sulfoxide cocktail. Int Urogynecol J. 2012;23(11):1533–1539.
   PubMed Web of Science ®Google Scholar
• Lim YN, Dwyer P, Murray C, et al. Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome. Int Urogynecol J. 2017;28(7):1085–1089.
   PubMed Web of Science ®Google Scholar
• Rawls WF, Cox L, Rovner ES. Dimethyl sulfoxide (DMSO) as intravesical therapy for interstitial cystitis/bladder pain syndrome: a review. Neurourol Urodyn. 2017;36(7):1677–1684.
   PubMed Web of Science ®Google Scholar
• Parsons CL, Housley T, Schmidt JD, et al. Treatment of interstitial cystitis with intravesical heparin. Br J Urol. 1994;73(5):504–507.
   PubMedGoogle Scholar
• Parsons CL, Zupkas P, Proctor J, et al. Alkalinized lidocaine and heparin provide immediate relief of pain and urgency in patients with interstitial cystitis. J Sex Med. 2012;9(1):207–212.
   PubMed Web of Science ®Google Scholar
• Cervigni M, Sommariva M, Tenaglia R, et al. A randomized, open-label, multicenter study of the efficacy and safety of intravesical hyaluronic acid and chondroitin sulfate versus dimethyl sulfoxide in women with bladder pain syndrome/interstitial cystitis. Neurourol Urodyn. 2017;36(4):1178–1186.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Moldwin R, Lee S, et al. Intravesical alkalinized lidocaine (PSD597) offers sustained relief from symptoms of interstitial cystitis and painful bladder syndrome. BJU Int. 2009;103(7):910–918.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Jain P, Shore N, et al. Continuous intravesical lidocaine treatment for interstitial cystitis/bladder pain syndrome: safety and efficacy of a new drug delivery device. Sci Transl Med. 2012;4(143):143ra100.
   PubMed Web of Science ®Google Scholar
• Ottem DP, Teichman JM. What is the value of cystoscopy with hydrodistension for interstitial cystitis? Urology. 2005;66(3):494–499.
   PubMed Web of Science ®Google Scholar
• Erickson DR, Kunselman AR, Bentley CM, et al. Changes in urine markers and symptoms after bladder distention for interstitial cystitis. J Urol. 2007;177(2):556–560.
   PubMed Web of Science ®Google Scholar
• Olson LE, Dyer JE, Haq A, et al. A systematic review of the literature on cystodistension in bladder pain syndrome. Int Urogynecol J. 2018;29(2):251–257.
   PubMed Web of Science ®Google Scholar
• Peeker R, Aldenborg F, Fall M. Complete transurethral resection of ulcers in classic interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct. 2000;11(5):290–295.
   PubMed Web of Science ®Google Scholar
• Payne RA, O’Connor RC, Kressin M, et al. Endoscopic ablation of Hunner’s lesions in interstitial cystitis patients. Can Urol Assoc J. 2009;3(6):473–477.
   PubMed Web of Science ®Google Scholar
• Malloy TR, Shanberg AM. Laser therapy for interstitial cystitis. Urol Clin North Am. 1994;21(1):141–144.
   PubMed Web of Science ®Google Scholar
• Rofeim O, Hom D, Freid RM, et al. Use of the neodymium: YAG laser for interstitial cystitis: a prospective study. J Urol. 2001;166(1):134–136.
   PubMed Web of Science ®Google Scholar
• Comiter CV. Sacral neuromodulation for the symptomatic treatment of refractory interstitial cystitis: a prospective study. J Urol. 2003;169(4):1369–1373.
   PubMed Web of Science ®Google Scholar
• Powell CR, Kreder KJ. Long-term outcomes of urgency-frequency syndrome due to painful bladder syndrome treated with sacral neuromodulation and analysis of failures. J Urol. 2010;183(1):173–176.
   PubMed Web of Science ®Google Scholar
• Gajewski JB, Al-Zahrani AA. The long-term efficacy of sacral neuromodulation in the management of intractable cases of bladder pain syndrome: 14 years of experience in one centre. BJU Int. 2011;107(8):1258–1264.
   PubMed Web of Science ®Google Scholar
• Marinkovic SP, Gillen LM, Marinkovic CM. Minimum 6-year outcomes for interstitial cystitis treated with sacral neuromodulation. Int Urogynecol J. 2011;22(4):407–412.
   PubMed Web of Science ®Google Scholar
• Ghazwani YQ, Elkelini MS, Hassouna MM. Efficacy of sacral neuromodulation in treatment of bladder pain syndrome: long-term follow-up. Neurourol Urodyn. 2011;30(7):1271–1275.
   PubMed Web of Science ®Google Scholar
• Wang J, Chen Y, Chen J, et al. Sacral neuromodulation for refractory bladder pain syndrome/interstitial cystitis: a global systematic review and meta-analysis. Sci Rep. 2017;7(1):11031.
   PubMedGoogle Scholar
• Smith CP, Radziszewski P, Borkowski A, et al. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871–875; discussion 875.
   Web of Science ®Google Scholar
• Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU Int. 2009;104(5):657–661.
   PubMed Web of Science ®Google Scholar
• Giannantoni A, Mearini E, Del Zingaro M, et al. Two-year efficacy and safety of botulinum A toxin intravesical injections in patients affected by refractory painful bladder syndrome. Curr Drug Deliv. 2010;7(1):1–4.
   PubMedGoogle Scholar
• Wang J, Wang Q, Wu Q, et al. Intravesical botulinum toxin A injections for bladder pain syndrome/interstitial cystitis: a systematic review and meta-analysis of controlled studies. Med Sci Monit. 2016;22:3257–3267.
   PubMed Web of Science ®Google Scholar
• Lee CL, Kuo HC. Intravesical botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician. 2013;16(2):109–116.
   PubMed Web of Science ®Google Scholar
• Andersen AV, Granlund P, Schultz A, et al. Long-term experience with surgical treatment of selected patients with bladder pain syndrome/interstitial cystitis. Scand J Urol Nephrol. 2012;46(4):284–289.
   PubMed Web of Science ®Google Scholar
• Erickson DR, Xie SX, Bhavanandan VP, et al. A comparison of multiple urine markers for interstitial cystitis. J Urol. 2002;167(6):2461–2469.
   PubMed Web of Science ®Google Scholar
• Keay S. Cell signaling in interstitial cystitis/painful bladder syndrome. Cell Signal. 2008;20(12):2174–2179.
   PubMed Web of Science ®Google Scholar
• Peters KM, Diokno AC, Steinert BW. Preliminary study on urinary cytokine levels in interstitial cystitis: does intravesical bacille Calmette-Guerin treat interstitial cystitis by altering the immune profile in the bladder? Urology. 1999;54(3):450–453.
   PubMed Web of Science ®Google Scholar
• Ogawa T, Homma T, Igawa Y, et al. CXCR3 binding chemokine and TNFSF14 over expression in bladder urothelium of patients with ulcerative interstitial cystitis. J Urol. 2010;183(3):1206–1212.
   PubMed Web of Science ®Google Scholar
• Gautam S, Tebo JM, Hamilton TA. IL-4 suppresses cytokine gene expression induced by IFN-gamma and/or IL-2 in murine peritoneal macrophages. J Immunol. 1992;148(6):1725–1730.
   PubMed Web of Science ®Google Scholar
• te Velde AA, Huijbens RJ, Heije K, et al. Interleukin-4 (IL-4) inhibits secretion of IL-1 beta, tumor necrosis factor alpha, and IL-6 by human monocytes. Blood. 1990;76(7):1392–1397.
   PubMed Web of Science ®Google Scholar
• Ueda T, Tamaki M, Ogawa O, et al. Improvement of interstitial cystitis symptoms and problems that developed during treatment with oral IPD-1151T. J Urol. 2000;164(6):1917–1920.
   PubMed Web of Science ®Google Scholar
• Rotondi M, Chiovato L, Romagnani S, et al. Role of chemokines in endocrine autoimmune diseases. Endocr Rev. 2007;28(5):492–520.
   PubMed Web of Science ®Google Scholar
• Bonecchi R, Bianchi G, Bordignon PP, et al. Differential expression of chemokine receptors and chemotactic responsiveness of type 1 T helper cells (Th1s) and Th2s. J Exp Med. 1998;187(1):129–134.
   PubMed Web of Science ®Google Scholar
• Sallusto F, Lenig D, Mackay CR, et al. Flexible programs of chemokine receptor expression on human polarized T helper 1 and 2 lymphocytes. J Exp Med. 1998;187(6):875–883.
   PubMed Web of Science ®Google Scholar
• Akiyama Y, Morikawa T, Maeda D, et al. Increased CXCR3 expression of infiltrating plasma cells in Hunner type interstitial cystitis. Sci Rep. 2016;6:28652.
   PubMed Web of Science ®Google Scholar
• Singh UP, Singh NP, Guan H, et al. The severity of experimental autoimmune cystitis can be ameliorated by anti-CXCL10 Ab treatment. PLoS One. 2013;8(11):e79751.
   PubMed Web of Science ®Google Scholar
• Niimi A, Igawa Y, Aizawa N, et al. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. Neurourol Urodyn. 2017 Oct 19. doi: 10.1002/nau.23431. [Epub ahead of print].
   Web of Science ®Google Scholar
• Corcoran AT, Yoshimura N, Tyagi V, et al. Mapping the cytokine profile of painful bladder syndrome/interstitial cystitis in human bladder and urine specimens. World J Urol. 2013;31(1):241–246.
   PubMed Web of Science ®Google Scholar
• Moroni G, Doria A, Ponticelli C. Cyclosporine (CsA) in lupus nephritis: assessing the evidence. Nephrol Dial Transplant. 2009;24(1):15–20.
   PubMed Web of Science ®Google Scholar
• Forsell T, Ruutu M, Isoniemi H, et al. Cyclosporine in severe interstitial cystitis. J Urol. 1996;155(5):1591–1593.
   PubMed Web of Science ®Google Scholar
• Sairanen J, Forsell T, Ruutu M. Long-term outcome of patients with interstitial cystitis treated with low dose cyclosporine A. J Urol. 2004;171(6 Pt 1):2138–2141.
   PubMed Web of Science ®Google Scholar
• Sairanen J, Tammela TL, Leppilahti M, et al. Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol. 2005;174(6):2235–2238.
   PubMed Web of Science ®Google Scholar
• Forrest JB, Payne CK, Erickson DR. Cyclosporine A for refractory interstitial cystitis/bladder pain syndrome: experience of 3 tertiary centers. J Urol. 2012;188(4):1186–1191.
   PubMed Web of Science ®Google Scholar
• Crescenze IM, Tucky B, Li J, et al. Efficacy, side effects, and monitoring of oral cyclosporine in interstitial cystitis-bladder pain syndrome. Urology. 2017;107:49–54.
   PubMed Web of Science ®Google Scholar
• Yang CC, Burks DA, Propert KJ, et al. Early termination of a trial of mycophenolate mofetil for treatment of interstitial cystitis/painful bladder syndrome: lessons learned. J Urol. 2011;185(3):901–906.
   PubMed Web of Science ®Google Scholar
• Tanaka H, Nakahara K, Hatanaka H, et al. [Discovery and development of a novel immunosuppressant, tacrolimus hydrate]. Yakugaku Zasshi. 1997;117(8):542–554.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Tyagi P, Huang HY, et al. Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cystitis. Neurourol Urodyn. 2011;30(3):421–427.
   PubMed Web of Science ®Google Scholar
• Kaneko G, Nishimoto K, Ito Y, et al. The combination therapy of prednisolone and tacrolimus for severe painful bladder syndrome/interstitial cystitis. Can Urol Assoc J. 2012;6(2):E46–E49.
   PubMed Web of Science ®Google Scholar
• Ueda Y, Tomoe H, Takahashi H, et al. Interstitial cystitis associated with primary Sjogren’s syndrome successfully treated with a combination of tacrolimus and corticosteroid: a case report and literature review. Mod Rheumatol. 2016;26(3):445–449.
   PubMed Web of Science ®Google Scholar
• Funahashi Y, Oguchi T, Goins WF, et al. Herpes simplex virus vector mediated gene therapy of tumor necrosis factor-alpha blockade for bladder overactivity and nociception in rats. J Urol. 2013;189(1):366–373.
   PubMed Web of Science ®Google Scholar
• Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J Urol. 2014;191(1):77–82.
   PubMed Web of Science ®Google Scholar
• Soucy F, Gregoire M. Efficacy of prednisone for severe refractory ulcerative interstitial cystitis. J Urol. 2005;173(3):841–843; discussion 843.
   PubMed Web of Science ®Google Scholar
• Taneja R, Jawade KK. A rational combination of intravesical and systemic agents for the treatment of interstitial cystitis. Scand J Urol Nephrol. 2007;41(6):511–515.
   PubMed Web of Science ®Google Scholar
• Cox M, Klutke JJ, Klutke CG. Assessment of patient outcomes following submucosal injection of triamcinolone for treatment of Hunner’s ulcer subtype interstitial cystitis. Can J Urol. 2009;16(2):4536–4540.
   PubMed Web of Science ®Google Scholar
• Mateu L, Izquierdo L, Franco A, et al. Pain relief after triamcinolone infiltration in patients with bladder pain syndrome with Hunner’s ulcers. Int Urogynecol J. 2017;28(7):1027–1031.
   PubMed Web of Science ®Google Scholar
• Zeidman EJ, Helfrick B, Pollard C, et al. Bacillus Calmette-Guerin immunotherapy for refractory interstitial cystitis. Urology. 1994;43(1):121–124.
   PubMed Web of Science ®Google Scholar
• Mayer R, Propert KJ, Peters KM, et al. A randomized controlled trial of intravesical bacillus Calmette-Guerin for treatment refractory interstitial cystitis. J Urol. 2005;173(4):1186–1191.
   PubMed Web of Science ®Google Scholar
• Propert KJ, Mayer R, Nickel JC, et al. Did patients with interstitial cystitis who failed to respond to initial treatment with bacillus Calmette-Guerin or placebo in a randomized clinical trial benefit from a second course of open label bacillus Calmette-Guerin? J Urol. 2007;178(3 Pt 1):886–890.
   PubMed Web of Science ®Google Scholar
• de Boer EC, de Jong WH, van der Meijden AP, et al. Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis. Urol Res. 1991;19(1):45–50.
   PubMedGoogle Scholar
• Ichihara K, Aizawa N, Akiyama Y, et al. Toll-like receptor 7 is overexpressed in the bladder of Hunner-type interstitial cystitis, and its activation in the mouse bladder can induce cystitis and bladder pain. Pain. 2017;158(8):1538–1545.
   PubMed Web of Science ®Google Scholar
• Stenton GR, Mackenzie LF, Tam P, et al. Characterization of AQX-1125, a small-molecule SHIP1 activator: part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. Br J Pharmacol. 2013;168(6):1506–1518.
   PubMed Web of Science ®Google Scholar
• Levi-Montalcini R, Skaper SD, Dal Toso R, et al. Nerve growth factor: from neurotrophin to neurokine. Trends Neurosci. 1996;19(11):514–520.
   PubMed Web of Science ®Google Scholar
• Freund-Michel V, Frossard N. The nerve growth factor and its receptors in airway inflammatory diseases. Pharmacol Ther. 2008;117(1):52–76.
   PubMed Web of Science ®Google Scholar
• Lowe EM, Anand P, Terenghi G, et al. Increased nerve growth factor levels in the urinary bladder of women with idiopathic sensory urgency and interstitial cystitis. Br J Urol. 1997;79(4):572–577.
   PubMedGoogle Scholar
• Okragly AJ, Niles AL, Saban R, et al. Elevated tryptase, nerve growth factor, neurotrophin-3 and glial cell line-derived neurotrophic factor levels in the urine of interstitial cystitis and bladder cancer patients. J Urol. 1999;161(2):438–441; discussion 441–432.
   PubMed Web of Science ®Google Scholar
• Qu HC, Zhang W, Yan S, et al. Urinary nerve growth factor could be a biomarker for interstitial cystitis/painful bladder syndrome: a meta-analysis. PLoS One. 2014;9(9):e106321.
   PubMed Web of Science ®Google Scholar
• Dmitrieva N, Shelton D, Rice AS, et al. The role of nerve growth factor in a model of visceral inflammation. Neuroscience. 1997;78(2):449–459.
   PubMed Web of Science ®Google Scholar
• Chuang YC, Fraser MO, Yu Y, et al. The role of bladder afferent pathways in bladder hyperactivity induced by the intravesical administration of nerve growth factor. J Urol. 2001;165(3):975–979.
   PubMed Web of Science ®Google Scholar
• Seki S, Sasaki K, Fraser MO, et al. Immunoneutralization of nerve growth factor in lumbosacral spinal cord reduces bladder hyperreflexia in spinal cord injured rats. J Urol. 2002;168(5):2269–2274.
   PubMed Web of Science ®Google Scholar
• Yoshimura N, de Groat WC. Increased excitability of afferent neurons innervating rat urinary bladder after chronic bladder inflammation. J Neurosci. 1999;19(11):4644–4653.
   PubMed Web of Science ®Google Scholar
• Evans RJ, Moldwin RM, Cossons N, et al. Proof of concept trial of tanezumab for the treatment of symptoms associated with interstitial cystitis. J Urol. 2011;185(5):1716–1721.
   PubMed Web of Science ®Google Scholar
• Wang H, Russell LJ, Kelly KM, et al. Fulranumab in patients with interstitial cystitis/bladder pain syndrome: observations from a randomized, double-blind, placebo-controlled study. BMC Urol. 2017;17(1):2.
   PubMedGoogle Scholar
• Kashyap M, Kawamorita N, Tyagi V, et al. Down-regulation of nerve growth factor expression in the bladder by antisense oligonucleotides as new treatment for overactive bladder. J Urol. 2013;190(2):757–764.
   PubMed Web of Science ®Google Scholar
• Kawamorita N, Yoshikawa S, Kashyap M, et al. Liposome based intravesical therapy targeting nerve growth factor ameliorates bladder hypersensitivity in rats with experimental colitis. J Urol. 2016;195(6):1920–1926.
   PubMed Web of Science ®Google Scholar
• Cockayne DA, Hamilton SG, Zhu QM, et al. Urinary bladder hyporeflexia and reduced pain-related behaviour in P2X3-deficient mice. Nature. 2000;407(6807):1011–1015.
   PubMed Web of Science ®Google Scholar
• Vlaskovska M, Kasakov L, Rong W, et al. P2X3 knock-out mice reveal a major sensory role for urothelially released ATP. J Neurosci. 2001;21(15):5670–5677.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chai TC. Effects of dimethyl sulphoxide and heparin on stretch-activated ATP release by bladder urothelial cells from patients with interstitial cystitis. BJU Int. 2002;90(4):381–385.
   PubMed Web of Science ®Google Scholar
• Sun Y, Keay S, De Deyne PG, et al. Augmented stretch activated adenosine triphosphate release from bladder uroepithelial cells in patients with interstitial cystitis. J Urol. 2001;166(5):1951–1956.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chai TC. Up-regulation of P2X3 receptor during stretch of bladder urothelial cells from patients with interstitial cystitis. J Urol. 2004;171(1):448–452.
   PubMed Web of Science ®Google Scholar
• Sun Y, Chai TC. Augmented extracellular ATP signaling in bladder urothelial cells from patients with interstitial cystitis. Am J Physiol Cell Physiol. 2006;290(1):C27–34.
   PubMed Web of Science ®Google Scholar
• Birder LA, Barrick SR, Roppolo JR, et al. Feline interstitial cystitis results in mechanical hypersensitivity and altered ATP release from bladder urothelium. Am J Physiol Renal Physiol. 2003;285(3):F423–429.
   PubMed Web of Science ®Google Scholar
• Moldwin R, Kitt M, Mangel J. A phase 2 study in women with interstitial cystitis/bladder pain syndrome (IC/BPS) OF the novel P2X3 antagonist AF-219. International Continence Society Annual Meeting; Abstract #23; Neurourol Urodyn. 2015;34(S3):S50.
   Google Scholar
• Marchand F, Perretti M, McMahon SB. Role of the immune system in chronic pain. Nat Rev Neurosci. 2005;6(7):521–532.
   PubMed Web of Science ®Google Scholar
• Schafers M, Svensson CI, Sommer C, et al. Tumor necrosis factor-alpha induces mechanical allodynia after spinal nerve ligation by activation of p38 MAPK in primary sensory neurons. J Neurosci. 2003;23(7):2517–2521.
   PubMed Web of Science ®Google Scholar
• Sommer C, Schmidt C, George A. Hyperalgesia in experimental neuropathy is dependent on the TNF receptor 1. Exp Neurol. 1998;151(1):138–142.
   PubMed Web of Science ®Google Scholar
• Sommer C, Lindenlaub T, Teuteberg P, et al. Anti-TNF-neutralizing antibodies reduce pain-related behavior in two different mouse models of painful mononeuropathy. Brain Res. 2001;913(1):86–89.
   PubMed Web of Science ®Google Scholar
• Fink DJ, Wechuck J, Mata M, et al. Gene therapy for pain: results of a phase I clinical trial. Ann Neurol. 2011;70(2):207–212.
   PubMed Web of Science ®Google Scholar
• Maeda D, Akiyama Y, Morikawa T, et al. Hunner-type (Classic) interstitial cystitis: a distinct inflammatory disorder characterized by pancystitis, with frequent expansion of clonal B-Cells and epithelial denudation. PLoS One. 2015;10(11):e0143316.
   PubMed Web of Science ®Google Scholar
• Nickel JC, Irvine-Bird K, Jianbo L, et al. Phenotype-directed management of interstitial cystitis/bladder pain syndrome. Urology. 2014;84(1):175–179.
   PubMed Web of Science ®Google Scholar
• Ueda T, Nakagawa M, Okamura M, et al. New cystoscopic diagnosis for interstitial cystitis/painful bladder syndrome using narrow-band imaging system. Int J Urol. 2008;15(12):1039–1043.
   PubMed Web of Science ®Google Scholar
• Regauer S, Gamper M, Fehr MK, et al. Sensory hyperinnervation distinguishes bladder pain syndrome/interstitial cystitis from overactive bladder syndrome. J Urol. 2017;197(1):159–166.
   PubMed Web of Science ®Google Scholar